”Orum has granted Vertex rights to conduct research using its TPD² approach to developing degrader-antibody conjugates (DACs), next-generation versions of antibody-drug conjugates (ADCs) which use antibodies to precisely deliver small molecule targeted protein degrader payloads to cancer cells and other targeted biological therapies.”
a new platform for ADC development….n... - Advanced Prostate...
a new platform for ADC development….no sorry, it’s DAC this time! not PCa related but hopefully soon
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
very interesting article on DAC’s as it’s still early phase
Not what you're looking for?
You may also like...
Big company buys a clinical research company focused on Actinium 225 (and others) FPI-2265
astra-something buys a Canadian company because they hate Canadians...no, sorry...ok, I will sound...
new approach: not PCa related but maybe in the future
counter intuitive but very interesting (reminds me of BAT somehow) will be tested on humans soon it...
not PCa related but promising in vivo therapy for cancer metastasis
”The polymer eliminates colorectal cancer liver metastases and prolongs mice survival, after only a...
Hyperthermia: I do not talk often about this but it’s a good approach
well, at 46 C degrees human cells die…I think that the best part of such treatment would be that...
New to this, but have followed for a year
Thank all of you for the things I have learned and the inspiration over the last year. I was...
PSA going down, but ALP increasing
Looks like a new medication will soon be approved for ADT - no more shots ! 
PSMA-targeted radiopharmaceutical clinical trials in the US
